Podcasts about validated

In the final episode of the year, We look into the controversial death of Marilyn Monroe. Co-hosts Gianni and Jeanie discuss the release of Russo's latest book, 'Mafia Secrets,' and James Patterson's 'The Last Days of Marilyn Monroe,' which both address the circumstances surrounding Monroe's death. Russo shares personal recollections from 63 years ago, emphasizing his role as an informant for Frank Costello. He reveals that Monroe's death was a cover-up involving figures like Bobby Kennedy and the Chicago mob, contradicting her official suicide verdict. The hosts reflect on the implications of Patterson's findings, which validate Russo's long-held assertions and recount Monroe's relationships and final days. They also share future plans for the podcast and Russo's upcoming events, while highlighting their determination to have Monroe's cause of death reclassified from suicide to homicide by her 100th birthday.

On this week's episode, we begin by discussing Jeff Kent's induction into the Baseball Hall of Fame after receiving 12 of 16 votes by the Contemporary Baseball Era Committee. From there, we discuss Devin Williams heading to the Mets, the Nationals and Mariners swapping a reliever for a top-prospect, the Blue Jays signing Cody Ponce from Korea, Emilio Pagan heading back to the Reds, the Pirates and Red Sox trading, Cedric Mullins heading to the Rays, and the Rockies hiring Josh Byrnes as GM. To wrap up, we each draft rosters made up of the best current players in baseball.

JCO Editorial Fellow Peter Li and author Dr. Jahanzaib Khwaja discuss the  ASH 2025 Simultaneous Publication article, "A New Validated Staging System for AL Amyloidosis With Stage lllC Defining Ultra-Poor Risk: AL International Staging System." TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's Editorial Fellow, and today, I am joined by Dr. Jahanzaib Khwaja on a new validated staging system on AL amyloidosis with stage lllC defining ultra-poor risk, AL International Staging System. This is a simultaneous publication that will be presented at this year's ASH Conference.  At the time of this recording, our guest has disclosures that will be linked in the transcript.  So, Dr. Khwaja, let's start off first: What would you say is the significance of your study? Dr. Jahanzaib Khwaja: Thank you very much. This is an important study in that, in the current treatment era, we have really improved outcomes of patients with systemic AL amyloidosis. Traditionally, the staging systems that have been employed, which are the Mayo 2012 and the European modification 2016, have been founded in eras where there were historic treatment protocols. So the significance of this new staging system is looking at outcomes of patients in the modern treatment era. That is patients who are treated with daratumumab-based treatments in the first line. And this is kind of the largest study which is externally validating a new prognostic model in the current treatment era with modern outcomes. Dr. Peter Li: Can you tell our listeners what is different about your new staging system? Dr. Jahanzaib Khwaja: The traditional staging systems, the Mayo 2012 and the European modification of 2016, looked at outcomes of patients with systemic AL amyloidosis with historic treatment protocols. And we know that they looked at outcomes according to an NT-proBNP and troponin, and in the Mayo 2012, they looked at it with the addition of the dFLC, which is the difference in the involved and uninvolved free light chain. Over the years, we have seen that outcomes have improved, and over decades, actually, outcomes are much better when we compare them to the previous decade. If we look at current treatment approaches, those traditional staging systems inadequately determine the poorest prognostic risk. So they are unable to tell us those who are going to perform poorly. Our current new validated staging system looks at the traditional NT-proBNP and troponin but uses the addition of the longitudinal strain. This is an echocardiographic parameter, and it is used widely in treatment centers who treat amyloidosis. This really identifies those ultra-high risk patients, and these are the patients who will perform poorly in current treatment protocols. And why is that important? Well, we need a robust staging system in the current treatment era which can stratify patients who will do well but also stratify those patients who do not do well. Because that is important for counseling patients, for risk stratification, for treatment approaches, and in the future, for designing clinical trials. Dr. Peter Li: And that is referring to the longitudinal strain greater than  -9% and NT-proBNP greater than 8,500 and then the high-sensitivity troponins greater than 50, which will define the new staging system. Can you talk more about how you picked these cutoffs and also what that alludes to in terms of the outcomes that you have discovered in this age of daratumumab-based therapy? Dr. Jahanzaib Khwaja: Yeah, that is a really excellent question because we have aimed to build upon traditional staging systems. So clinicians have used these traditional models for many, many years, and they have robustly underpinned our stratification of patients and how we counsel patients. So we didn't want to change some of these well-established thresholds, but we wanted to test them in the current treatment era. So the NT-proBNP of 8,500 and the high-sensitivity troponin of 50 were the traditionally used thresholds. And they actually stand the test of time. But we found that longitudinal strain additionally and independently predicts outcome independent of these other biomarkers. It is independent actually as a continuous variable, so you can cut this at a number of different stratification points and find independence. But we wanted to determine and discriminate those with the poorest outcomes. So we validated a longitudinal strain threshold of greater than  -9% by deriving this from a dataset of patients with the traditionally highest risk. Those are with European stage lllB. And looked at the optimal threshold with time-dependent ROC analysis. So we did this in our derivation cohort and then validated this externally in our external validation cohort amongst a number of centers in Europe, in the US, and in the UK. And it is important to note because longitudinal strain is an echocardiographic parameter, and traditionally the limitations are considered to be inter-vendor and inter-operator variability and intra-operator variability, and there are challenges with reproducibility of some of these measurements. So that is often cited as a limitation. But we found, when we have externally validated this across different centers using different platforms, actually the threshold of -9% is independently predictive of poorer outcomes independent of the traditional NT-proBNP and troponin thresholds, and it is robustly predictive of poorest outcomes. We know that those with stage lllC have a median overall survival of 4 to 7 months in the modern treatment era. And if we sub-stratify these by patients treated with daratumumab, outcomes have improved, but still, even if we look at daratumumab-treated patients, one-year overall survival is still only around 50 percent. So these are a poor risk group in the modern treatment era. Dr. Peter Li: Which kind of makes sense in a way because this kind of predicts whether they have amyloid-related cardiomyopathy. So I think this all tracks with our listeners. But given the poor outcomes even with daratumumab-based therapies, do you think this new staging system would change practice, if at all? Dr. Jahanzaib Khwaja: Yeah, I think that is a really good point because I think it comes to the question of why we use a staging system. What are its applications? I think one of the key things we think about in the clinic is how do we counsel patients when we first talk to them about their diagnosis. So there is a lot of information, but predominantly people want to know, what is my outlook going to look like? And as I say, in the bortezomib treatment era, 2010 to 2020, we used to say you have stage lllB, you have very poor outcomes, median survival maybe around six months. We have shown here that actually those with lllB have much better outcomes definitely over 12 months, up to 24 months in those with daratumumab-based therapies. So we need to counsel them in a different way. We then also need to say, "Well, who are the ultra-high risk?" So we said those with the longitudinal strain of greater than -9% with the traditional NT-proBNP and troponin cutoffs. And those patients will have poor outcomes. We need to talk about palliation. We need to talk about alternate treatment approaches. And then importantly for the community is about treatment and clinical trial design. So again, traditionally the traditional high-risk group lllB used to be considered an exclusion for all major trials. So these were excluded in the ANDROMEDA study, which led to the approval of daratumumab-based therapy, and multiple other trials. And we show here that actually patients with lllB should not be excluded from these studies because they do have good outcomes. And I think we make the important point that those with lllC, who do have poor outcomes, they need a different treatment approach, and we need to think about stratifying these patients differently. So perhaps the next modality of treatment will be the anti-fibril antibodies or a mode of treatment which can clear antibodies or clear the amyloid fibrils from the organs and reduce the organ toxicity early on. We know that those with lllC have poor outcomes particularly within the first year, and organ dysfunction really predominates here. So a different treatment approach is required, and we need to design trials specifically for these patients which look beyond anti-plasma cell clone therapy but also look at clearing the amyloid fibrils and improving organ function as this is predominantly the cause of death in these patients. Dr. Peter Li: That's an excellent point right there.  Do you foresee any limitations to this new staging system, or can you comment on is there potentially a better way to refine this staging criteria in the future? Dr. Jahanzaib Khwaja: Yeah, I think that is a really excellent point to consider, that staging systems always need refining across treatment eras. So we have looked at the bortezomib era, and then we have validated this in the daratumumab-based era. We know that amongst different countries access to treatment varies. We know that there are a number of factors which determine your health-related outcomes. That's access to healthcare, speed of diagnosis, access to tertiary diagnostics, ability to biopsy, and then supportive care. And I think our staging system highlights the importance of organ dysfunction predominantly causing death early on. And I think that as treatments improve this should be refined. So the expectation I think is, as we have better anti-plasma cell directed therapies, and as we hopefully develop anti-fibril antibodies and anti-fibril clearance drugs, that we will need to revalidate new models to effectively prognosticate in this treatment era. And I also think that as we become a bit more sophisticated with our approaches, we know that this can be refined in the future looking at other prognostic factors with regards to healthcare outcomes. I would say one of the strengths, however, of this model is that it builds on the traditional model, and it's quite simple to use. You just have the NT-proBNP and the troponin, and then longitudinal strain, which is used quite frequently in amyloid centers, and an echocardiogram is used in essentially all patients for diagnosis. So I think it will certainly be quite practical. But certainly I think, as you say, as treatment approaches change over time, and as we have further options in the future, we will need to refine prognostication. Dr. Peter Li: For the listeners out there, let's say someone comes in our clinic and we diagnose them with stage lllC amyloidosis. Can you comment on what clinical trials are out there that potentially they can refer their patients to? You mentioned anti-fibril therapy, which I think would be the way of the future. Can you kind of comment what you know at this current stage and point listeners in the right direction? Dr. Jahanzaib Khwaja: This is the challenge in amyloidosis. We don't have specific trials that are looking at those with the highest risk. And at present, even the ISA International Guidelines talk about risk according to the old treatment approaches and discuss attenuating our current chemotherapy approaches. And I think that for clinicians out there who identify those at the highest risk, it is really important to have a multidisciplinary approach, to consider palliation and palliative services early, and really work with your fellow cardiologists and renal physicians and neurologists to enable the best supportive care you have in order to deliver this anti-plasma cell directed therapy. We know that actually you only need for most patients small amounts of doses of chemotherapy to get good clonal responses, and we have seen that even in the bortezomib era that actually they have good CR rates and more impressive CR rates with daratumumab. But because of the organ dysfunction, it can be really challenging to deliver these doses. And supportive care is going to be really important particularly for these challenging patients. The future will be designing clinical trials that are appropriate for these patients. At present, we currently don't have available options, but I think the more we gather this data, the more we work collaboratively as a community, we will be able to mobilize our resources and get the best outcomes for these patients.  Dr. Peter Li: First build the field of dreams and then hopefully more therapies will arrive in the future. Thank you so much, Dr. Khwaja, for speaking about the JCO article, "A New Validated Staging System for AL Amyloidosis With Stage lllC Defining Ultra-Poor Risk: AL International Staging System," and for all your valuable input today. Dr. Jahanzaib Khwaja: Thank you very much. Dr. Peter Li: Make sure to check out the presentation at this year's ASH Conference taking place from December 6 to December 9. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Rikki ran an experiment with her husband where she validated every concern he had. Here's how it went.

Limelight is building the infrastructure layer for B2B creator marketing, processing payments and managing campaigns for companies spending six figures monthly on creator partnerships. With $2.1 million in funding from Signal to Noise Ratio, Ascend Ventures, Savion Ventures, and strategic angels including the head of AI at Amazon and the former Chief Product Officer at Lyft, Limelight powers creator programs for Clay, Webflow, ZoomInfo, and Bill.com. In this episode of BUILDERS, we sat down with David Walsh, Founder and CEO of Limelight, to learn how he validated the market by interviewing 100+ creators, why he deliberately chose not to build an agency despite customer demand, and how his platform tracks engagement data at scale to prove ROI for performance-focused buyers. Topics Discussed: The pivot from referral software to B2B creator infrastructure after 100+ creator interviews How creator attitudes shifted from refusing brand partnerships to actively monetizing Clay's playbook: building custom Clay tables for creators before asking them to post Why Limelight chose to power agencies rather than compete with them The data infrastructure required to justify $100K+ monthly creator budgets Tracking organic engagement, converting content to paid ads, and attributing pipeline The split between brand/social buyers and performance/demand gen buyers Launching social listening to challenge legacy social media management platforms GTM Lessons For B2B Founders: Validate with 100+ user interviews before pivoting: David didn't just chat with a handful of potential users—he conducted and recorded over 100 interviews with B2B creators, asking detailed questions about monetization interest, partnership preferences, and content strategies. He then repeated this process with marketing leaders. This level of research rigor before committing to a pivot is rare but critical when entering emerging categories. The depth of qualitative research gave him conviction to make a contrarian bet when most creators were still refusing brand partnerships. Build where network effects are structural, not hoped for: David specifically chose a creator marketplace after a previous marketplace failure because the unit economics included built-in virality. When Limelight pays a creator $10,000, that creator has tens of thousands of followers who see the transaction result (the sponsored content). Every payment notification becomes inbound interest. He understood that in consumer marketplaces you compete on supply quality, but in creator marketplaces the supply actively markets your platform. Founders should identify whether their marketplace has structural network effects in the transaction itself, not just theoretical ones. Target micro-creators with niche audiences over vanity metrics: The counterintuitive insight: creators with 10,000-25,000 followers often outperform those with 100,000+ in B2B because deal sizes are $25K-$50K, not $100 sunglasses. Smaller creators have higher engagement rates, unsaturated audiences, authentic expertise in specific domains, and haven't been "bought and sold for" yet. When brands face the choice between a 100K-follower creator at $2,000 per post with 200 likes versus a 25K-follower creator at $1,000 per post with 300 likes, they irrationally choose the larger following. Founders should educate buyers that in B2B, targeted influence within specific buyer committees matters more than reach. Build data infrastructure to win performance buyers, not just brand buyers: Limelight tracks every piece of content in real-time (not waiting weeks for creator screenshots), monitors all engagement and segments it by ICP fit, provides self-reported attribution from demo forms, tracks website traffic spikes correlated to posting schedules, and generates qualified lead lists from content engagement. This comprehensive data layer is what allows demand gen leaders to reallocate spend from paid channels. The market is splitting 50/50 between brand/social buyers and performance/demand gen buyers—the latter has larger budgets and treats creator spend like paid media that requires attribution. Founders entering new marketing channels should build attribution infrastructure from day one, not as an afterthought. Deliberately choose infrastructure over services even when customers ask for help: Despite customers like Webflow, ZoomInfo, and Bill.com spending $100K+ monthly and requesting more hands-on support, David chose to build product and enable agencies rather than hire account managers and become a service business. His reasoning: people have tried to replace agencies in recruiting for decades and failed because buyers want the human in the middle. The bigger opportunity is being the infrastructure that powers all agencies, not competing with them. This fork-in-the-road decision—hire CSMs and influencer marketing managers versus build more product—defines whether you're building a scalable platform or a services business disguised as SaaS. Use your first customer to custom-build product, then scale it: Clay became Limelight's first customer when the platform was early. David essentially custom-built features for Clay's creator program, learning their workflow for building Clay tables for creators, their onboarding process, and their approach to creative freedom. This deep partnership gave Limelight the product foundation to scale from managing 20 creators to 200+ for Clay within nine months, then apply those learnings to other customers. Rather than building in a vacuum, founders should find a sophisticated first customer willing to co-develop the product, even if it means initially building something custom. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here:  https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

Join me live with Jyllian Clarke as we discuss the power of self discovery, building confidence so that you show up Authentically you!Jyllian Clarke is an executive coach who's passionate about helping people lead and live with authenticity. She's the author of Pure Excellence: The Joy in Finding You and the creator of I AM ME: 100% Validated!®, a guided self-discovery experience that empowers individuals to embrace who they are, fully and unapologetically. A former security senior executive turned coach, Jyllian now creates spaces for individuals and teams to recognize their excellence, and build the confidence, connection, and clarity needed to show up as their most authentic selves.More about Jyllian: https://isocoachingllc.com Get her book: Pure Excellence: The Joy in Finding You https://amzn.to/48833PVFor more shows and information like this: Checkout https://aboutthatwallet.com Disclaimer: The information in this podcast is for general informational and educational purposes only and does not constitute financial, legal, or tax advice. Please consult with a qualified professional for advice tailored to your individual circumstances.Episode 317

Is AI forcing a total rethink of what we hire for — and how we measure it? If skills now “expire” in a couple of years, what signal should TA teams use at the top of the funnel to predict who will succeed when the job inevitably changes?Meet Fiadhna McEvoy C.Psychol, MCIPD, Psychometric Innovation Director at Arctic Shores — a business psychologist with nearly 20 years' experience spanning occupational assessment, organisational development and psychometric innovation. At Arctic Shores, Fiadhna leads the design of task-based assessments built on cognitive science. And in this episode, she lifts the lid on a brand-new way to measure learning agility, the workplace capability everyone's talking about.Join host Robert Newry and guest Fiadhna McEvoy as they discuss:

Did the Texans' win over Jacksonville validate DeMeco Ryans' philosophy? ITL breaks it down. Then, Figgy's Mixtape features a wild story about an argument over chicken and eggs leading to a shooting, Charlie Sheen reuniting with Mad Max after 30 years, and more off-the-wall headlines.

SOFA-2 is here — a major advance in assessing organ dysfunction in critical illness

Today's special guest is legendary make-up artist Val Garland! She and Charlie discuss Gaga's prosthetics, Miley's magic moment and Vivienne Westwood's ultimate compliment...Find Val on Instagram and TikTok @thevalgardland and buy her book, Validated, in all good bookshops.Here's one handy link to find My Wardrobe Malfunction on all our socials - and check out our website at mywardmal.com.We always love hearing from you - tag us @mywardmal or send a message or voice note to help@mywardmal.com. If you like this episode, please subscribe, check out the others and give us a five-star rating and review.My Wardrobe Malfunction is a Clearwood Media production.Hosted by Charlie HedgesEdited by Sam RhodesMusic by Duo DestinoCreated and produced by George Thwaites Hosted on Acast. See acast.com/privacy for more information.

tiun is building auth and payment infrastructure that consolidates two traditional categories into one streamlined solution. By combining social login with instant payment functionality, tiun eliminates the standard account creation and credit card entry flow, reducing user onboarding to a two-click process. Operating as merchant of record, tiun serves online entertainment businesses, content creators, news publishers, and SaaS platforms. The company currently reaches 10 million users monthly through customer website placements and is growing transactions 15-20% month-over-month. In this episode of Category Visionaries, Sandro Zweig shares how tiun evolved from targeting news publishers to building a broader entertainment ecosystem, the challenges of creating a market for a combined category, and the data-driven approach to proving ROI before scaling. Topics Discussed: Evolution from news publisher focus to entertainment and SaaS ecosystem strategy Consolidating auth and payment infrastructure into a single category Case study metrics: 20% uplift in paying users with under 1% subscription cannibalization The 2.5x lead generation improvement versus traditional subscription models Building market-specific ecosystems as a B2B2C go-to-market strategy DACH penetration strategy before US expansion Achieving organic exposure through customer website placement Reducing integration complexity to drive adoption in an emerging category GTM Lessons For B2B Founders: Geographic density creates B2B2C flywheels: tiun's go-to-market prioritizes ecosystem density within a single market over broad geographic distribution. Users discover tiun on one platform, then encounter it across 3-4 additional properties in their consumption pattern, creating recognition and repeat usage. This required penetrating DACH (100 million people, single language, unified regulations) before considering US expansion. For B2B2C products where end-user familiarity drives business adoption, concentrate on saturating one market until the consumer-side network effect reduces enterprise sales friction. Validate with 6-12 month pilot data before scaling: tiun ran contained pilots with 3-4 customers for a full year before pursuing their long-tail market. This produced case studies showing 20% paying user uplift and under 1% cannibalization—metrics that directly addressed the primary objection (subscription revenue risk). Sandro notes this extended validation period became essential because "there is no market for it yet. We're creating the market." When creating a new category, resist scaling pressure until you have multi-month data that quantifies business outcomes and neutralizes the biggest adoption barriers. Strategic revenue trade-offs accelerate ecosystem development: tiun deliberately adjusted pricing to "pay out more to our businesses to grow a bit faster"—prioritizing transaction volume and ecosystem density over near-term take rate. This economics decision reflected that their value proposition strengthens with ecosystem scale: users need to encounter tiun across multiple properties for the solution to deliver its full promise. When building network effects or marketplace dynamics, model whether lower monetization drives the velocity needed to reach critical mass faster than optimizing for immediate margins. Integration speed directly determines category creation velocity: Sandro identified that "if the sales cycle is too long and integration is too complicated, people won't do it. Especially since it's a product that doesn't exist and there is no market for it yet." They focused on reducing implementation to 2-3 weeks, recognizing that asking companies to replace existing auth and payment infrastructure requires minimal switching costs. For emerging categories where customers must displace incumbent solutions, integration complexity often determines adoption more than feature superiority. Build investor relationships 12+ months before raises: Sandro emphasizes starting fundraising conversations well before needing capital: "If you decide, oh, I need to fundraise right now, then you will automatically get into a cash crunch. Because by the time you have established all the relationships, it just takes such a long time that you run out of money where it really hurts your negotiation power." Treat investor relationship development as continuous rather than transactional—similar to enterprise pipeline development where deals close from relationships built quarters earlier. //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role.  Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM  

Most of us look to our folks, teachers, or spouse for glorious validation. After all, it puts confidence in our step! But often times, writers can't wait for someone else to wake up and notice how incredible they are... so let me teach you how to validate yourself in today's show. You'll gain momentum, confidence, and a sense of flow. AND, over a short bit of time, you'll find your new validated energy attracting wonderful opportunities.Speaking of opportunities!! Check out the amazing membership I'm offering below. It's on super saver right now.The Writer's Membership is on Super Duper sale for the Fall, back-to-school season (right now). And it's just $395 instead of the full price of $2,000.And it is for the person:- who wants writing to be easier- who wants to communicate more effectively- who wants to capture stories on paper- who wants to be led by The Supernatural as well as the practical- who desires a social influence with stories that stand out- who wants to elevate their personal image- who wants to share blogs or a book with a receptive audience- who wants to live happily and honestly in their own skinIt begins January 2026, and runs through the end of June, but as a Super Duper early bird member, you will get free invitations through the fall season to join me on Zoom so we can begin our expansion together.You may sign up here: https://square.link/u/3cTFwymFWrite to Coach Debby anytime: https://www.coachdebby.com/connectSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We rejoice in love, acceptance, and grace…as well we should.  But what about judgment, fear, and obedience. We Ought to Be... 1. Motivated by the Fear of God's Judgment v.6-7      -The Gospel is available for all, but it won't be available forever! 2. Validated by the Fate of God's Judgment v.8 3. Devastated by the Fullness of God's Judgment v.9-11      - Hell will be worse than you can imagine 4. Dedicated to the Faithfulness of God's Judgment v.12-13 What should we long and pray for? The lost without Christ—Repentance The dying with Christ—Relief The living with Christ (us)—Revival  

This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the Dermatology and Therapy website and by using this link:https://link.springer.com/article/10.1007/s13555-025-01551-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Protect your family with our 1-minute free parent quiz https://www.smartsocial.com/newsletterJoin our next weekly live parent events:  https://smartsocial.com/eventsEpisode Summary:In this episode of the Smart Social.com podcast, host Josh Ochs sits down with Dr. Francisco Duran, superintendent of Arlington, Virginia schools, to discuss key challenges and strategies for managing student screen time and social media use. They delve into issues like phone addiction, mental health impacts of social media, and AI in education. Dr. Duran shares insights from his district's successful implementation of policies to reduce screen time, including eliminating cell phones during school hours. They also discuss the importance of parent engagement and provide practical tips for maintaining an ongoing dialogue with children about their online activities. The episode underscores the value of fostering real-world connections and community involvement for student well-being and success.Become a Smart Social VIP (Very Informed Parents) Member: https://SmartSocial.com/vipDistrict Leaders: Schedule a free phone consultation to get ideas on how to protect your students in your community https://smartsocial.com/partnerDownload the free Smart Social app: https://www.smartsocial.com/appdownloadLearn about the top 190+ popular teen apps: https://smartsocial.com/app-guide-parents-teachers/View the top parental control software: https://smartsocial.com/parental-control-software/The SmartSocial.com Podcast helps parents and educators to keep their kids safe on social media, so they can Shine Online™

Interview with Gan-Ochir Zunduisuren, Managing Director of Asian Battery Metals PLCRecording date: 15th October 2025Asian Battery Metals (ASX:AZ9) is emerging as a focused critical minerals developer in Mongolia, strategically positioned at the doorstep of Asian consumption markets. Led by Managing Director Gan-Ochir Zunduisuren, a mining engineer with 22 years of experience including a board position at Rio Tinto's Oyu Tolgoi copper operation, the company is advancing a portfolio of copper, nickel, and gold projects in southwestern Mongolia's prospective Central Asian orogenic belt.The company's flagship Oval copper-nickel project has delivered significant validation through selection for BHP's prestigious Xplor accelerator program in 2023. As one of only seven companies chosen globally from 250 applicants - and the sole Asian representative - Asian Battery Metals received $500,000 USD to prove the concept of a magmatic mafic intrusion-related copper-nickel sulfide system. This third-party technical endorsement has been reinforced by encouraging metallurgical results, with initial test work achieving 89-95% copper recovery and concentrate grades of 18.5-24%, meeting industry benchmarks for economic viability.With approximately A$30 million in market capitalization and A$7-8 million deployed across exploration programs, the company has established 800 meters of continuous mineralization at Oval, with widths ranging from 50 to 80 meters. Recent drilling has extended mineralization to 290 meters depth, suggesting potential for deeper extensions along feeder conduit structures. The company is also advancing regional targets including MS1, located six kilometers south of Oval with geophysical signatures potentially larger than the main discovery, supporting a hub-and-spoke development model where multiple deposits could share centralized processing infrastructure.Complementing the copper-nickel focus, Asian Battery Metals is completing due diligence on the Maikhan Uul VMS copper-gold system, located just eight kilometers from Oval. Recent drilling confirmed more than 20 meters of massive sulphide mineralization with historic grades of approximately 1.7% copper and 1 gram per tonne gold, plus a high-grade shallow gold zone grading over 15 g/t. The company expects to complete this acquisition within four months, adding diversification and supporting the multi-deposit cluster strategy that Managing Director Gan-Ochir described as essential to achieving the company's goal of "more than 20 million tons of economic resources or potentially producing 50,000 tons of metals."Mongolia's maturation as a mining jurisdiction provides crucial support for development pathways. Over the past 15 years, the country has opened 20-30 new mines, improved infrastructure substantially, and developed multiple financing options including international financial institutions, domestic banks, and Chinese offtake arrangements. This evolution, combined with proximity to Asian markets and an established contractor mining sector, positions Asian Battery Metals to advance its projects efficiently in a jurisdiction that has demonstrated it can support world-class operations like Rio Tinto's Oyu Tolgoi copper mine.View Asian Battery Metals' company profile: https://www.cruxinvestor.com/companies/asian-battery-metalsSign up for Crux Investor: https://cruxinvestor.com

Device Nation sits down for an inspiring conversation with THE world's preeminent authority on bone infection, Professor Martin McNally!We talk Osteomyelitis, FRI, Girdlestone Society, antibiotic stewardship, Solario, ABX delivery carriers,rowing and a product worthy of consideration for your bag, your OR….CERAMENT G!In this episode you will learn:Where we are on the DAIRWhere the word “Girdlestone” came from How antibiotic-impregnated cement can create resistanceThe concept of "Antibiotic Stewardship”Best practices to prevent intra-op and field infectionsThe genesis of CERAMENT GGuinness Stout….to chill or not to chill?……..and so much more!!Martin McNally is Honorary Consultant in Limb Reconstruction at the Oxford Bone Infection Unit in the Nuffield Orthopaedic Centre, Oxford University Hospitals and King James IV Professor at the Royal College of Surgeons of Edinburgh.He has a particular interest in osteomyelitis, infected fractures and non-unions. He has published over 200 peer-reviewed papers, reviews and book chapters. His current research and clinical studies focus on diagnosis and treatment options together with assessment of outcomes and quality of life for infection patients. He has been a champion of multi-disciplinary working in bone infection and was lead surgeon in the Oxford Unit for 20 years. Validated protocols and treatment methods designed in Oxford are now widely used around the worldHe is Past-President of the European Bone and Joint Infection Society (EBJIS) and the Girdlestone Orthopaedic Society. He is a member of the EFORT Scientific and Education Committees and Co-chair of the International Fracture-related Infection (FRI) Group.Lastly, big announcement for those attending AAHKS this year…can't wait to see you in Grapevine!Room: Dallas 6Friday, October 24th6:30-8:30 AMOVIVA Trial: https://pubmed.ncbi.nlm.nih.gov/30699315/CERAMENT G: https://www.bonesupport.com/en-eu/products/cerament-g/JBJS Paper: https://pubmed.ncbi.nlm.nih.gov/36047024/Professor McNally Research Works: https://www.researchgate.net/profile/Martin-Mcnally-2This is an orthopedic expert discussion on the use of BONESUPPORT's product CERAMENT(R) G. Some of the uses discussed here may not be approved or cleared by FDA. The expert is independent and the content is not in any way influenced by BONESUPPORT. For complete product information, including indications, contraindications, warnings, precautions and potential adverse events, see package insert.Support the show

HAVE A VOICE ⬇️ https://www.rarepatientvoice.com/rp/thepicklejar

Most of us look to our folks, teachers, or spouse for glorious validation. After all, it puts confidence in our step! But often times, writers can't wait for someone else to wake up and notice how incredible they are... so let me teach you how to validate yourself in today's show. You'll gain momentum, confidence, and a sense of flow. AND, over a short bit of time, you'll find your new validated energy attracting wonderful opportunities.Speaking of opportunities!! Check out the amazing membership I'm offering below. It's on super saver right now.The Writer's Membership is on Super Duper sale for the back-to-school season (right now). And it's just $395 instead of the full price of $2,000.And it is for the person:- who wants writing to be easier- who wants to communicate more effectively- who wants to capture stories on paper- who wants to be led by The Supernatural as well as the practical- who desires a social influence with stories that stand out- who wants to elevate their personal image- who wants to share blogs or a book with a receptive audience- who wants to live happily and honestly in their own skinIt begins January 2026, and runs through the end of June, but as a Super Duper early bird member, you will get free invitations through the fall season to join me on Zoom so we can begin our expansion together. You may sign up here: https://square.link/u/3cTFwymFWrite to Coach Debby anytime: https://www.coachdebby.com/connectSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Valerie Greenberg is here! We discussed her new playbook, YOU'VE BEEN VALIDATED, and her mom's advice on being your own best friend.Her warmth and tenacity shine as a Lifestyle Expert and Media Personality. It felt like reconnecting with my new best friend! Grab YOU'VE BEEN VALIDATED available today, Amazon. You can connect with Valerie Greenberg on Instagram @valgreenberg

This week on Two Parents & A Podcast, we're diving into the benefits of family dinner (we're feeling VALIDATED), baby shower do's and don'ts (including one MAJOR mistake we made), and an in-depth review of the Karen Read trial (yep, you read that right). Before all that… we're in Vancouver!!!! Our FIRST international episode (unless someone digs up that one from the lost files). Harrison rapid-fires his travel recs to help YOU plan your next trip (sorry in advance—he named a chain lol). We also get into how our parents' habits shaped us, the joy of Sunday night dinners, and a new rule that has completely SAVED movie night. Then the fun stuff—our picks for the absolute BEST gifts for new moms (the last one may surprise you). And in Things We DMed: the most attractive (and unattractive) hobbies a man can have, plus… Gen Z is apparently sucking on WHAT?! OK LOVE YOU GUYS!!! 00:00:00 Welcome back to Two Parents & A Podcast! 00:04:02 Rapid-fire Vancouver recommendations for your next trip 00:07:05 Our craziest airport horror stories 00:12:32 How your parents' habits shape who you are today 00:14:40 Sunday night family dinner 00:20:15 Our thoughts on the Karen Read trial 00:27:15 New rule that solved our movie night problem 00:31:46 Baby shower do's and don'ts 00:37:33 The absolute best gifts for new moms 00:47:45 The most attractive (and unattractive) hobbies a man can have 00:52:00 Gen Z's new anxiety trend: PACIFIERS?!  00:52:50 #1 parenting hack: family dinners 00:55:08 THANK YOU FOR LISTENING!!!  #twoparentsandapod --------------------------------------------------------------- Thank you to our sponsors this week: Hers: Start your initial free online visit today at https://www.forhers.com/ALEX for your personalized weight loss treatment options. Hers Weight Loss is not available everywhere. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Restrictions apply. Wegovy® and Ozempic® are not compounded. Actual price depends on product and plan purchased. Cozy Earth: Head to https://www.CozyEarth.com and use code TWOPARENTS for up to 40% off! And if you get a Post-Purchase Survey, make sure to let them know you heard about Cozy Earth right here!  Quince: Give your summer closet an upgrade—with Quince. Go to https://www.Quince.com/Alex for free shipping on your order and three hundred and sixty-five-day returns.  --------------------------------------------------------------- Listen to the pod on YouTube/Spotify/Apple: https://www.youtube.com/@twoparentsandapod https://open.spotify.com/show/7BxuZnHmNzOX9MdnzyU4bD?si=5e715ebaf9014fac https://podcasts.apple.com/us/podcast/two-parents-a-podcast/id1737442386 --------------------------------------------------------------- Follow Two Parents & A Podcast: Instagram | https://www.instagram.com/twoparentsandapod TikTok | https://www.tiktok.com/@twoparentsandapod Follow Alex Bennett: Instagram | https://www.instagram.com/justalexbennett TikTok | https://www.tiktok.com/@justalexbennett Follow Harrison Fugman: Instagram | https://www.instagram.com/harrisonfugman TikTok | https://www.tiktok.com/@harrisonfugman --------------------------------------------------------------- Powered by: Just Media House – https://www.justmediahouse.com/ --------------------------------------------------------------- Learn more about your ad choices. Visit megaphone.fm/adchoices

We learn that what was true for Daniel is still true now: “There is a God in heaven.” Where human strategies fail, God begins to work. Don't you want to be part of what God is up to in your community, in your family, in your world?

As we continue our teaching series through the book of Daniel, we're walking through Nebuchadnezzar's confusing dream in Daniel, Chapter 2. Through this wild and startling story, we learn to view our culture the way Daniel viewed his—not through assimilation, not through separation, but through transformation.

Dr. Jeff Tarrant discusses his research on psychic mediums, focusing on brain activity using quantitative EEG. He highlights the involvement of the right parietal lobe, often referred to as the "God spot," in mediumship. Dr. Jeff Tarrant has studied around 20 psychic mediums and a few channelers, noting significant brainwave changes during mediumship, including increased gamma and slow waves. He also explores psychokinesis, noting improved performance when the left frontal lobe is inhibited. Dr. Tarrant emphasizes the importance of quieting the ego and achieving a flow state for effective psychic abilities. Dr. Jeff Tarrant discussed his journey into Qigong and energy healing, starting in the early 90s in Missouri. He described his initial experiences with energy healing, including sending and receiving energy, and later studies involving Pranic Healing. A small study with EEG measurements showed significant brain wave changes during healing sessions, indicating real effects beyond placebo. Dr. Tarrant emphasized the importance of relaxation in Qigong and the potential for energy to be used internally or externally, as in martial arts.Become a supporter of this podcast: https://www.spreaker.com/podcast/next-level-soul-podcast-with-alex-ferrari--4858435/support.

In a surprising turn, the LDS Church has quietly validated the long-disputed 1886 Revelation given to John Taylor, a document that fundamentalists have clung to for over a century as divine proof that plural marriage was never meant to end. In this episode, Lindsay and Bryan dig into the origins of the revelation, the secret …

Time for a deep dive into the second PHASE of the world class business cycle and an offer's journey from $0 to $200K+ in revenue: Validating your signature offer to $10K in sales/revenue. This is the MOST UNDER-SUPPORTED and OVER-LOOKED phase of the business cycle, and is the KEY to easier, faster and simpler results for your business and to creating a world class business. Most coaches, personal development providers and business owners rush ahead trying to grow an offer that has not been VALIDATED first. Once you validate your offer - you have a validated marketing & sales process that uniquely works to sell your offer. The sooner you figure this out - the sooner you can get to doing what you do best, which is DELIVERING your offer and serving the people your business is here to serve. In today's episode you'll find out the 6 steps needed to validate any offer in your business. This is key to building, growing and leading a world class, 6-figure (and beyond) business that makes a positive difference in the world, that you're proud of and that positions you as a leader in your niche and industry. It's my FAVOURITE phase of the business journey, and the phase that I love to support my clients with the most (as it requires the most support). Happy listening! Apply for My World Class Program here: www.leticiaringe.com/shesworldclass Take my FREE World Class Training here: www.leticiaringe.com/worldclass Download my FREE Menstrual Magic Journal here: www.leticiaringe.com/menstrualmagicjournal Podcast Show Notes at: www.leticiaringe.com/podcast

In a surprising turn, the LDS Church has quietly validated the long-disputed 1886 Revelation given to John Taylor, a document that fundamentalists have clung to for over a century as divine proof that plural marriage was never meant to end. In this episode, Lindsay and Bryan dig into the origins of the revelation, the secret …

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

July 16, 2025. Week 29. What is a natural history study (NHS)?  And why do we care? We care because we haven't done this before, heal those born with disease. Natural history studies, which examine the progression of a disease over time, can be either retrospective or prospective. Retrospective studies analyze existing data, like medical records, while prospective studies collect new data over time. Both types are valuable for understanding a disease's course and informing research and treatment strategies. ⁠NHS are critical for clinical trial design.  Size and Quality matter.  Validated scales are better than PROs regardless of what the current rhetoric is. What's going on now? USA - https://curesyngap1.org/resources/studies/syngap1-ProMMiS/ - 135+ over three sites, some with FOUR visits, and counting - Adding GCP - Collaborating with world class institutions and excellent clinicians at Stanford, Children's Colorado and, of course, CHOP. USA - https://Citizen.Health/partners/srf has almost 300 patients! Retrospective Health Data. USA - https://rare-x.org/syngap1/ is where we collect PROs. Australia - Dr. Sheffer is running a study, talk to her or Dani. Latin America - SYNGAP1 Argentina with others joining. Europe - https://www.patre.info/syngap1/  Key takeaways for Industry SYNGAP1 is well positioned to work with… Vlasskamp and Wiltrout are published, Citizen Health is growing & ProMMiS is truly exceptional – and growing, and Rare-X is collecting eight key PROs.   Additionally, there are significant international efforts in Australia, Latin America & Europe. Census: https://curesyngap1.org/blog/syngap1-census-2025-update-55-in-q2-2025-total-1636/  If you are in industry and thinking about starting another NHS for your asset, please don't.  Please instead partner with existing PAGs and NHS studies in your key geographies to move faster, have bigger N and not waste precious patients time, we need to accelerate drug development not slow it down by diluting patients and clinicians between too many studies. Baseline papers on SYNGAP1: 1998 - Huganir - SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family - https://pubmed.ncbi.nlm.nih.gov/9581761/ 2009 - Michaud - Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation - https://pubmed.ncbi.nlm.nih.gov/19196676/ 2013 - Carvill - Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1 - https://pubmed.ncbi.nlm.nih.gov/23708187/ 2019 - Vlasskamp - SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy - https://pubmed.ncbi.nlm.nih.gov/30541864/ 2023 - Rong - Adult Phenotype of SYNGAP1-DEE - https://pubmed.ncbi.nlm.nih.gov/38045990/ 2024 - Wiltrout - Comprehensive phenotypes of patients with SYNGAP1-related disorder reveals high rates of epilepsy and autism - https://pubmed.ncbi.nlm.nih.gov/38470175/ Pubmed is at 28 (so less than one a week…) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2025-2025&timeline=expanded&sort=date&sort_order=asc   CURE SYNGAP1 CONNECT https://curesyngap1.org/curesyngap1connect/   SHARE BLOOD TO THE SRF BIOBANK AT CB! Read here for more information: https://curesyngap1.org/blog/fueling-research-syngap1-combinedbrain-biorepository-roadshow/    VOLUNTEER  Join us: https://curesyngap1.org/volunteer-with-srf/    SOCIAL MATTERS - 4,238 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,400 followers with 575 Videos on YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,302 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    NEWLY DIAGNOSED? New families have resources here! https://syngap.fund/Resources      Podcasts, give all of these a five star review! https://cureSYNGAP1.org/SRFApple   https://podcasts.apple.com/us/channel/syngap1-podcasts-by-srf/id6464522917    Episode 175 of #Syngap10  #RareDisease #PatientAdvocacy #SYNGAP1 #SynGAP #ProMMiS

Today on the Tech Bytes podcast we explore NVDs, or Nokia Validated Designs, for enterprise data center networks. NVDs are developed to address a broad set of customer requirements and undergo extensive testing of hardware, software, and traffic. We talk with sponsor Nokia about its validation process, customer benefits, NVD use cases, technical details, and... Read more »

Today on the Tech Bytes podcast we explore NVDs, or Nokia Validated Designs, for enterprise data center networks. NVDs are developed to address a broad set of customer requirements and undergo extensive testing of hardware, software, and traffic. We talk with sponsor Nokia about its validation process, customer benefits, NVD use cases, technical details, and... Read more »

Diane Montagna uncovers new evidence confirming CDF Report: Erodes Vatican Narrative on Traditional Latin Mass Restrictions. Full Substack story by Diane Montagna here: https://dianemontagna.substack.com/p/… https://ChristianPatriotBook.com Pre-Order Dr. Marshall's new book Christian Patriot. Watch this new podcast episode by CLICKING HERE Today's Sponsors: https://purehealthresearch.com — Get 35% off when you try Liver Health Formula today and use code Taylor at checkout! https://nsti.com/checkout/?rid=pJNK69 This is the NSTI discount link to receive your $1 jump start at New Saint Thomas Institute for your Catholic Bible in a Year, Catholic Bible Cheat Sheet, and Catholic Lifetime Reading List and 10 Catholic Courses from Dr. Taylor Marshall.

In this episode of Caring Greatly, K. Elliott Higgins III, MD, is Director of Health and Wellbeing for UCLA's Department of Anesthesiology and Perioperative Medicine, shares the origin of the Wellbeing Influencers Survey for Healthcare (WISH). The survey initiative began when Dr. Higgins and his team wanted more insight into specific drivers and barriers for wellbeing. He describes the process by which he and his team collaborated with an extended team of content experts to identify the eight critical drivers of team member wellbeing and then validate a set of questions that accurately assess these drivers and reliably predict key outcomes including burnout, intent to leave and professional fulfillment. Finally, Elliott shares the ways that the WISH survey is helping to facilitate culture change and team alignment by creating a shared lexicon and helping teams focus on changes that have the biggest impact on safety and wellbeing. He also outlines the team's efforts to test the survey's value in multi-center trials within anesthesia, as well as trials in other specialties, with hopes that the survey will help to improve cultures of care team safety and wellbeing across the healthcare ecosystem. The views and opinions expressed in this podcast are those of the speakers and do not necessarily reflect the views or positions of Stryker.

Do you ever feel like sharing your feelings with your spouse only leads to defensiveness, frustration, or being completely misunderstood? Like you're trying to express something real and vulnerable, but instead you end up managing their reaction or feeling more alone than before? You're not broken (and neither is your marriage) but this episode explains exactly what's getting in the way of the emotional safety and connection you crave.In this episode, I'll walk you through one of the most common (and least talked about) dynamics that makes emotional validation feel impossible in marriage, and how you can change it.Tune in to discover:What the “I failed” filter is, and how it sabotages connectionWhy your spouse may not be validating you, even if they think they areA realistic mindset shift around what validation actually looks likeThe biggest validation trap couples fall into (and how to get out of it)Scripts to use when you want to feel heard, and when your partner needs to feel cared forFREE Marriage Shutdown Checklist: https://marriedafterkids.com/marriage-shutdown?utm_source=podcast&utm_medium=links&utm_campaign=MSoptinConnect with me for a FREE Married After Kids Intervention Call: https://marriedafterkids.satoriapp.com/offers/277730-married-after-kids-intervention-callFollow me on Instagram so you don't miss a thing! www.instagram.com/marriedafterkids

And, if so... WHY IS IT ALWAYS BROKEN??? TODAY ON THE SHOW: Nic's neck nub! WAR of the ROSES! Rich is VALIDATED! The time you SHOULD have died...but didn't! + SOmuchMORE!!See omnystudio.com/listener for privacy information.

Today we are bringing you something special! A behind the scenes look atone of the businesscreator.club office hours. We had a high-impact discussion on moving from one-on-one sales to scalable one-to-many models with content. We answered questions about launching podcasts, repurposing content, and growing a valuable network. We also discussed how to leverage collaborations to build authority and boost sales. Here are some of the top moments. 1. Validated the Interview Model as a Sales Engine - The interview model is still viable—when done strategically. Use it to build real relationships and create opportunities for collaboration and sales. 2. Leveraged “Ladder of Influence” Framework - Target guests based on tiers (C → B → A). Start with peers and move up by leveraging each guest's network. 3. Created the “Fastest Path to Cash” Flow - Focus first on direct relationships (the guest) and convert them or collaborate with them to reach their audience. This is quicker than cold ads or SEO. 4. Clarified the Expert Positioning in Interviews - Shift from “reporter” to “collaborator” by injecting your own insights in interviews. This positions you as an expert too. 5. Set the Playbook for Growth via Ask Framework - After every interview, ask these 3 things to ensure a constant flow of leads and opportunities. Timestamped Overview: [00:00] Intro: Behind the scenes of the Business Creator Club's first Q&A session [02:30] Surya's question: Is the interview model still worth it in 2025? [05:00] The ladder of influence: How to strategically choose your guests [07:30] Podcasting as a lead-gen tool: building rapport with your guest [10:00] Breaking down podcast discoverability, retention, and what actually works [13:40] Paid reach vs. organic growth: When should you spend to accelerate? [17:00] Why most interview podcasts sound the same — and how to stand out [20:30] Flipping the script: How to position yourself as an expert within the interview [23:30] Leveraging your guests for offers, referrals, and warm intros [27:00] Fastest Path to Cash: Using 1:1 conversations to unlock 1:many opportunities [30:45] How to build value before you make the ask [34:10] Surya's lightbulb moment: From interview to relationship engine [37:35] Dana's question: How do you get guests when you're just starting out? [41:00] How to turn one interview into a referral chain of ideal guests [44:25] Final tips: Use content as a vehicle to connect and collaborate Connect with Fonzi: Facebook Instagram LinkedIn Twitter Connect with LUISDA: Facebook Instagram LinkedIn Twitter Subscribe to the podcast on Youtube, Apple, Spotify, Google, Stitcher, or anywhere you listen to your podcasts. You can find this episode plus all previous episodes here. If this episode was helpful, please don't forget to leave us a review by clicking here, and share it with a friend.

The Tragically Hip Top Forty Countdown: Song 18 — Claire from Ann ArborHey, it's jD. And welcome to the wide open middle of the countdown — that beautiful, feral terrain where deep cuts go to become legends and personal faves start to collide with consensus picks.This week on The Tragically Hip Top Forty Countdown, I'm joined by one of our most thoughtful and eloquent membersHIPers: Claire from Ann Arbor. We talk about discovering The Hip as a millennial from the U.S., falling hard thanks to Hockey Night in Canada, and how a steady diet of CBC and her dad's hockey tapes led her straight to 50 Mission Cap. (That's right — before she even knew the song, she knew the legend of Bill Barilko. That's parenting done right.)But what really makes this one hit different? Claire's lived experience as a disabled fan navigating concerts, fandom, and feeling safe in the crowd. Her reflections on inclusivity, identity, and finding community through The Hip are honest, funny, moving, and — in true TTHTop40 fashion — a little nerdy in the best possible way.We're not just counting down songs here. We're collecting stories. Claire's is one you'll be glad you heard.

Ever feel like you should be further ahead by now? Like no matter how much you do, it still doesn't feel like enough?In today's episode, I'm walking you through 8 powerful signs that you're actually doing far better than you give yourself credit for. If you've been doubting your progress, stuck in self-comparison, or just feeling behind in life — this one's for you.

Why did I get sick as a 25-year-old? When my habits looked healthy and my eating was better than most others!?  In this episode of BodyHacking - Build a Better You, we explore the transformative power of quantum medicine and frequency scanning. Join me as I recount my recent experience with a quantum medicine practitioner who revealed fascinating insights about my cellular health, genetic predispositions, and hidden health risks. From extraordinary cellular health to underlying liver issues, acidity levels, and dormant infections, I share how these findings validate the power of nutrition, supplementation, and targeted wellness strategies. Tune in to learn how quantum medicine could uncover hidden health truths that standard tests may miss and why prevention truly is the only cure.Send us a textSupport the showIf you LOVED this episode, please LEAVE A REVIEW and help us grow!Connect with Michaela?www.foodchangeslives.com/Youtube @FoodChangesLives Instagramwww.instagram.com/michaela_morrell/ Fbwww.facebook.com/FoodChangesLives www.facebook.com/groups/omega3experience DISCLAIMER: Welcome to BodyHacking - Build a Better You podcast! Please note that the content provided on this channel is for informational purposes only and should not be considered medical advice. The information shared here is based on personal experiences, research, and general knowledge. Always consult with a qualified healthcare professional before making any health-related decisions. Additionally, some of the products and services mentioned on this channel may be affiliate links. This means I may earn a commission if you purchase through these links. Rest assured, I only recommend products and services that I personally use and trust in my daily life. Things I have spent countless hours researching and feel are th...

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠It's YOUR time to #EdUpIn this episode, brought to YOU by HigherEd PodConYOUR guest is Brady Colby, Head of Market Research, Validated InsightsYOUR host is ⁠⁠⁠⁠Dr. Joe SallustioHow are trade schools reaching the "hockey stick" growth phase?Why do trade schools now have higher favorability than Ivy League institutions?How are revenues growing at 11.1% while enrollment rises 4.9%?What differentiates public & proprietary trade school performance?Why aren't traditional institutions seeing the same growth with similar programs?Topics include:Defining trade schools in the higher education landscapeAnalyzing the 60% enrollment in non-degree programsExamining growth areas in healthcare, green energy maintenance & cosmetologyUnderstanding the projected 6.6% annual growth through 2030Exploring whether trade schools "cannibalize" traditional enrollmentListen in to #EdUpDo YOU want to accelerate YOUR professional development?Do YOU want to get exclusive early access to ad-free episodes, extended episodes, bonus episodes, original content, invites to special events, & more?Then ⁠⁠⁠⁠⁠⁠BECOME A SUBSCRIBER TODAY⁠⁠ - $19.99/month or $199.99/year (Save 17%)!Want to get YOUR organization to pay for YOUR subscription? Email ⁠⁠⁠EdUp@edupexperience.comThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ & ⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Joe Sallustio⁠⁠⁠⁠● Join YOUR EdUp community at ⁠⁠⁠⁠⁠⁠⁠⁠⁠The EdUp Experience⁠⁠⁠⁠⁠⁠⁠⁠⁠!We make education YOUR business! 

Join me as I chat with Justin Mares, Founder of Kettle and Fire, as he explains his methodical approach to validating Kettle and Fire before fully launching it in 2014-2015. He created a basic landing page with a PayPal checkout to test if people would pay $29.99 for bone broth, achieving a 30% conversion rate despite having no actual product. The conversation highlights how modern AI tools have dramatically lowered barriers to entry for entrepreneurs testing new business ideasTimestamps:• 00:00 - Intro• 01:05 - The Scale of Kettle and Fire• 01:20 - The Initial Idea and Inspiration• 02:16 - Validating Market Demand• 04:03 - Addressing Skepticism on Market Research• 06:00 - Testing Pricing and Demand• 08:48 - Bing Ads and Early Revenue• 12:22 - Leveraging AI for Business Today• 13:42 - Finding Passion-Driven Problems• 15:28 - Identifying Trends and Tools• 20:15 - ChatGPT 4o for Initial Product DesignKey Points• Justin shares how he validated and launched Kettle and Fire, now a nine-figure bone broth business• He used a minimal landing page, Fiverr logo, and Bing ads to test market demand before creating the product• The validation process focused on identifying if enough people wanted the product and if they would pay enough1) The "Day Zero" validation strategy that worked:Justin wanted bone broth for his own health but couldn't find it online. Before creating anything, he asked two critical questions:• How many people actually want this?• Will they pay enough to make it a viable business?Smart validation = less risk.2) Finding your TRUE market size:Justin didn't rely on gut feeling. He went where his potential customers hung out:• Paleo forums• CrossFit communities• Reddit threads• Mark's Daily AppleHe found FANATIC engagement around bone broth recipes, sourcing, and benefits3) The Google Trends hack Justin checked macro trends to confirm his micro observations.He wasn't looking to build a 9-figure business at 24 - just wanted to make $10K/month with his brother.Simple math: A few thousand customers spending a few hundred dollars a year = viable business.4) The $15 MVP that ACTUALLY validated demand:• $9.99 domain ([bonebroths.com](http://bonebroths.com/))• $5 logo from Fiverr• Basic landing page on UnbounceNo product. No fancy design. Just a simple page highlighting benefits that his target audience cared about:- Healing leaky gut- Convenience- Organic ingredients5) The GENIUS pricing strategy:Justin priced at $29.99 for 16oz - 6X MORE than grocery store broth!His thinking: "If people will pay this much for a product they've never tasted from a sketchy landing page, they REALLY want it."High price = strong signal of demand.6) The checkout flow was HILARIOUSLY janky:"Order Now" button → Justin's personal PayPalThat's it. That was the entire checkout.And guess what? PEOPLE STILL BOUGHT IT! After spending just $100 on Bing ads (yes, Bing!), he made nearly $500 in revenue.7) The honest follow-up that built trust:After validating demand, Justin emailed every customer:"We don't have the product yet. I can either refund you in full or give you 50% off when we ship in a few weeks."Most chose the discount, giving him runway to actually create the product.8) From validation to execution:It took 8 months to figure out production and scaling.But because he KNEW people wanted it and would pay for it, he had the confidence to push through the hard parts.9) How would he do it TODAY with AI tools?• Better landing pages using tools like Bolt.new• Sentiment analysis across Reddit/Twitter• AI-generated product designs (as shown in the podcast)10) The bigger lesson for aspiring founders:Focus on problems YOU care deeply about.The best ideas come from the frontier where you're already spending your time.11) AI is LEVELING the playing field:One person with strong conviction + AI tools can now build products that previously required entire teams.12) Want to find YOUR startup idea?Justin's advice:• Find a problem that lights you up• Circle that problem until you find interesting solutions• Validate with real customers willing to pay• Use AI to accelerate everythingLCA helps Fortune 500s and fast-growing startups build their future - from Warner Music to Fortnite to Dropbox. We turn 'what if' into reality with AI, apps, and next-gen products https://latecheckout.agency/BoringAds — ads agency that will build you profitable ad campaigns http://boringads.com/BoringMarketing — SEO agency and tools to get your organic customers http://boringmarketing.com/Startup Empire - a membership for builders who want to build cash-flowing businesses https://www.startupempire.coFIND ME ON SOCIALX/Twitter: https://twitter.com/gregisenbergInstagram: https://instagram.com/gregisenberg/LinkedIn: https://www.linkedin.com/in/gisenberg/FIND JUSTIN ON SOCIALX/Twitter: https://x.com/jwmaresHis Blog: https://justinmares.com/

Karl Ravech and Buster chat following the Padres' sweep of the Braves to start the season. They discuss a validating series win for San Diego, the Yankees deploying the torpedo bats, Aaron Judge's magical start, Rafael Devers struggling as a new DH, if Roki Sasaki will land in the minor leagues soon, and other first weekend impressions. Then, Sarah Langs takes The Numbers Game into a new era. CALL THE SHOW: 406-404-8460 EMAIL THE SHOW: BleacherTweets@gmail.com REACH OUT ON X: #BLEACHERTWEETS 9:13 Clown Car with Karl Ravech 25:49 The Numbers Game with Sarah Langs 27:24 Bleacher Tweets Learn more about your ad choices. Visit podcastchoices.com/adchoices

Karl Ravech and Buster chat following the Padres' sweep of the Braves to start the season. They discuss a validating series win for San Diego, the Yankees deploying the torpedo bats, Aaron Judge's magical start, Rafael Devers struggling as a new DH, if Roki Sasaki will land in the minor leagues soon, and other first weekend impressions. Then, Sarah Langs takes The Numbers Game into a new era. CALL THE SHOW: 406-404-8460 EMAIL THE SHOW: BleacherTweets@gmail.com REACH OUT ON X: #BLEACHERTWEETS 9:13 Clown Car with Karl Ravech 25:49 The Numbers Game with Sarah Langs 27:24 Bleacher Tweets Learn more about your ad choices. Visit podcastchoices.com/adchoices

PREVIEW: Colleague Richard Epstein remarks that DOD is likely to be found improperly validated without a Senate-approved leader. More later. 1958